BioTech IP Review

Assignee: BioMarin Pharmaceutical Inc.
Publication Number: US 20250161466 A1
Filed: November 15, 2024
Publication Date: May 22, 2025

What It Covers

This published patent application discloses novel therapeutic conjugates consisting of:

• A phenylalanine ammonia‑lyase (PAL) enzyme — the core catalytic protein used to break down phenylalanine in patients with phenylketonuria (PKU).
• A poly(oligo(ethylene glycol)methacrylate) (POEGMA) polymer covalently attached to the enzyme, which:
  • Reduces the immune response against the enzyme (immune‑masking), an improvement over conventional PEGylated PAL therapies like PALYNZIQ®.
  • Provides faster and potentially more favorable pharmacokinetics (absorption, distribution, metabolism) than existing PAL treatments.

The application further discloses pharmaceutical compositions of these POEGMA‑PAL conjugates, methods of reducing blood phenylalanine levels, and treating PKU or PAH deficiency with these compositions.

Why This Is Important

• Enhances core product area: BioMarin’s current PKU product PALYNZIQ® (pegylated PAL) has significant clinical use but has limitations related to immune responses; this invention aims to overcome those limitations, potentially offering a next‑generation therapeutic.
• Commercial potential: A more tolerable or more effective PAL therapy could expand patient uptake, improve outcomes, and extend market leadership — supporting long‑term revenue streams in the PKU market.
• Strategic IP position: it represents BioMarin’s forward IP strategy to strengthen and extend its portfolio in metabolic disease‑focused biologics.

---

Note: Because US 20250161466 A1 is a published patent application (pending), it has not yet issued as a granted patent. But this application supports what’s likely to be one of BioMarin’s most commercially valuable innovations advancing toward grant — one that could shape future PKU enzyme therapy offerings once protection is secured.